What did @medspaslo actually say?
Nurse Kristie ran through a rapid-fire list of "best peptide" picks covering eight health goals: GHK-Cu for skin, retatrutide for weight loss, "the Wolverine Stack" (BPC-157 plus TB-500) for recovery, thymosin alpha-1 for immunity, NAD and thymosin alpha-1 for longevity, Semax for mood, PT-141 for sex drive, "PAP4" for nerve pain, and DSIP for deep sleep. The format was casual and confident, framed around a nurse's personal favorites rather than a clinical protocol. No dosing was mentioned, which is one thing they got right. But when a healthcare provider calls something a "gamechanger" on Instagram to 67,000 viewers, the bar for accuracy gets higher, not lower. Several of these compounds have legitimate research behind them. Several others are being sold on name recognition and bodybuilding forum lore more than on peer-reviewed evidence.
Does the science back this up?
It depends enormously on which peptide you pick. The evidence spectrum here is wide. GHK-Cu for skin has real, if modest, support. Retatrutide for weight loss is backed by phase 2 trial data. But "the Wolverine Stack" and DSIP are another story entirely.
Starting with the solid ground: GHK-Cu (copper peptide) has shown collagen-stimulating effects in cell studies and some small human trials (Pickart and Margolina, 2018, Biomolecules). Retatrutide is a legitimate triple agonist (GLP-1, GIP, glucagon) with a phase 2 trial published in the New England Journal of Medicine in 2023 showing meaningful weight reduction, though it is still in clinical development and not FDA-approved. Thymosin alpha-1 has immunomodulatory data, primarily from sepsis and hepatitis B contexts (Camerini et al., 2010, Thymus). PT-141 (bremelanotide) is actually FDA-approved for hypoactive sexual desire disorder in women, so that claim has the strongest regulatory footing of any on the list.
Then there is the softer end. BPC-157 and TB-500 recovery claims rest almost entirely on rodent studies. DSIP (delta sleep-inducing peptide) has decades-old Soviet-era research and almost no modern controlled human data. "PAP4" is not a standard clinical nomenclature, which makes independent verification close to impossible.
What did they get wrong (or right)?
They got PT-141 right. It has FDA approval. Give credit where it is due. Retatrutide is a real compound with real trial data, though calling it a "peptide for weight loss" without noting it is not approved and not the same as Ozempic or Mounjaro is a meaningful omission.
The "Wolverine Stack" framing is where this gets genuinely problematic. Branding an unapproved combination of two peptides with essentially no human clinical trials as a recovery protocol, and naming it after a comic book character with superhuman healing, is marketing dressed up as medicine. BPC-157 does not have a single completed, published randomized controlled trial in humans as of 2024. TB-500's human data is similarly absent outside of theoretical mechanisms. Presenting these as established clinical tools to a 67,000-person audience is an overreach.
Calling NAD a peptide is also technically wrong. NAD (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is sometimes administered via IV at med spas alongside peptide protocols, but grouping it under "favorite peptides" reflects either a loose use of terminology or a category error that should have been corrected before posting.
What should you actually know?
Most peptides discussed in this video are compounded, meaning they are mixed by compounding pharmacies and are not FDA-approved drugs. This does not make them automatically dangerous, but it does mean the purity, dosage consistency, and long-term safety data that come with approved drugs simply do not exist for most of these compounds. Compounded BPC-157 is not the same as a drug that has passed phase 3 trials. Full stop.
If you are considering any of these therapies, the questions worth asking your provider are: What human trial data supports this use? Is this compound legal to prescribe in my state? What are the known side effect profiles? And critically, is this being recommended because the evidence supports it, or because it is popular right now?
A nurse recommending peptides on Instagram is not the same as a peer-reviewed treatment guideline. That does not mean the recommendations are wrong. It means you should treat them as a starting point for a conversation, not a prescription.